Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Autism Dev Disord. 2019 Jan;49(1):173–184. doi: 10.1007/s10803-018-3688-5

Table 2:

Association between cord plasma adiponectin levels and ASD risk in children in the Boston Birth Cohorta

Unadjusted Model 1 Model 2 Model 3
Total n ASD n OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Continuous 674 40 0.51 (0.35, 0.75) 0.001 0.50 (0.33, 0.77) 0.002 0.47 (0.30, 0.74) 0.001 0.36 (0.21, 0.62) <0.001
Quartile
Q1 167 20 Ref Ref Ref Ref
Q2 170 8 0.36 (0.16, 0.85) 0.02 0.39 (0.15, 1.01) 0.05 0.38 (0.14, 1.03) 0.06 0.32 (0.11, 0.91) 0.03
Q3 169 7 0.32 (0.13, 0.77) 0.01 0.40 (0.15, 1.10) 0.08 0.38 (0.13, 1.12) 0.08 0.23 (0.07, 0.77) 0.02
Q4 168 5 0.23 (0.08, 0.62) 0.004 0.14 (0.04, 0.46) 0.001 0.13 (0.04, 0.45) 0.001 0.08 (0.02, 0.34) 0.001
a

Adiponectin was entered as a continuous variable in one model and categorical variable in another model

Model 1: Adjusted for child’s sex, race, maternal education, maternal age, parity, smoking status, pre-pregnancy BMI, diabetes status, follow-up time

Model 2: Model 1 + gestational age

Model 3: Model 1 + early childhood adiponectin